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Membrane activitykbone designs with stability towards proteases are of interest for several
pharmaceutical applications including intracellular delivery. The present study concerns the cellular uptake
and membrane-destabilising effects of various cationic chimeras comprised of alternating N-alkylated β-
alanine and α-amino acid residues. For comparison, homomeric peptides displaying octacationic
functionalities as well as the Tat47–57 sequence were included as reference compounds. Cellular uptake
studies with ﬂuorescently labelled compounds showed that guanidinylated chimeras were taken up four
times more efﬁciently than Tat47–57. After internalisation, the chimeras were localised primarily in vesicular
compartments and diffusively in the cytoplasm. In murine NIH3T3 ﬁbroblasts, the chimeras showed
immediate plasma membrane permeabilising properties, which proved highly dependent on the chimera
chain length, and were remarkably different from the effects induced by Tat47–57. Finally, biophysical studies
on model membranes showed that the chimeras in general increase the permeability of ﬂuid phase and gel
phase phosphatidylcholine (PC) vesicles without affecting membrane acyl chain packing, which suggests that
they restrict lateral diffusion of the membrane lipids by interaction with phospholipid head groups. The α-
peptide/β-peptoid chimeras described herein exhibit promising cellular uptake properties, and thus
represent proteolytically stable alternatives to currently known cell-penetrating peptides.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionThe delivery of biomacromolecular drugs across membrane
barriers of mammalian cells still remains a major challenge for
compounds with an intracellular pharmacological site of action. A
promising means of achieving this is by the use of so-called cell-
penetrating peptides (CPPs) [1]. At effective concentrations CPPs are
associated with remarkably low toxicity and have therefore been
applied to transport a wide range of molecular cargo types into cells
[2]. In addition to biomacromolecules (peptides, proteins and nucleic
acids), the cargos can comprise small molecule drugs, imaging agents,
or particulate systems (e.g. nanoparticles).
CPPs were initially discovered as peptide domains of viral proteins
that were able to mediate shuttling of proteins between cells. Early
reports suggested that addition of HIV-1 transactivating (Tat) protein
to cell cultures resulted in transactivation of the HIV-1 promoter upon5 35 33 60 30.
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l rights reserved.cell membrane permeation of Tat [3,4]. The Drosophila antennepedia
transcription protein was subsequently found to possess similar
transduction properties [5]. Minimal peptide sequence requirements
for transduction of these proteins were later deduced [6,7], and the
peptides were shown to be capable of transporting other macro-
molecules [8] into cells. Many additional CPPs have been identiﬁed
[9,10], and CPPs constitute nowavery heterogeneous and large group of
peptides, often subdivided into classes, e.g. the polycationic or arginine-
rich peptides (e.g., Tat-peptides, penetratin, and Arg8 [11]) aswell as the
amphipathic peptides (e.g., transportan [12]). CPPsmayalsobe classiﬁed
as fragments of naturally occurring proteins or peptides (Tat-peptides
and penetratin), as entirely synthetic peptides (e.g., MPG [13], Arg8, Pep-
1 [14], YTA2 [15]), or as chimeras such as transportan. The subdivision of
CPPs is rather ambiguous, however, since no clear deﬁnition of criteria
exists. Also, there seems to be no or little homology between primary or
secondary structure among CPP classes, but a common feature is that
CPPs are often rich in basic residues (Arg, Lys) that may interact with
negatively charged cell surface-bound molecules.
The cellular uptake mechanisms of CPPs is debated and may very
likely vary depending on their structure, cargo and type of target cell
[16–18]. For guanidinium-rich peptides it is generally suggested that
the peptides interact with negatively charged heparan sulfate
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dependent endocytotic uptake via macropinocytosis [19]. In addition
to endocytosis, direct passage of peptides through the plasma
membrane is also believed to be an important uptake mechanism
[20]. Peptides are suggested to escape from endosomes via perturba-
tion of and translocation over endosomal membranes in a membrane
potential-dependent way [20].
Another extensively studied class of peptides is the so-called
antimicrobial peptides (AMPs). These are naturally occurring innate
host-defence agents that act as a ﬁrst-line protection against invasive
microorganisms, and they have been found interesting as alternatives
to current antibiotic treatment strategies due to an assumed low
tendency towards resistance development owing to their interaction
with the cellmembrane of the pathogens [21]. Cationic AMPs generally
consist of 12–50 amino acids, of which at least 20% are cationic [21],Fig. 1. Chemical structures of α-peptide/β-peptoid chimeras and ﬂuoreand they are able to kill a broad spectrum of microorganisms while
preserving host-cell integrity [21,22]. Cationic AMPs presumably act
mainly at the membrane level [22,23], but their translocation into the
cytoplasm is not uncommon [24,25], which has led to the application
of membrane-crossing AMPs as templates for the design of CPPs [26].
We recently reported on the synthesis and preliminary investiga-
tion of antimicrobial properties of proteolytically stable α-peptide/β-
peptoid chimeras [27], and found it interesting to test whether these
cationic oligomers also might have potential as CPPs. The molecular
design is based on alternating N-alkylated β-alanine (β-peptoid) units
and α-amino acid units (Fig. 1). The rationale behind this design was
to gain structure-promoting effects and lipophilicity from the
unnatural chiral β-peptoid residues, while the α-amino acid residues
provide the cationic functionalities and intramolecular hydrogen
bonding capability. The chimeras were shown to possess promisingscently labelled peptides and chimeras used in the current study.
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(CD) spectroscopy indicated the presence of secondary structure in
both aqueous and organic solutions [27,28]. The chimeras proved
highly resistant to enzymatic degradation in vitro [27], and at their
effective antimicrobial and antiplasmodial concentrations, they were
generally non-hemolytic [27,28]. However, we also found that
alterations of erythrocyte membranes could be observed at low
concentrations for some of these oligomers, showing that the
compounds may affect membranes without leading to detrimental
lysis [28]. These features encouraged us to investigate the interaction
of these compounds with membranes in greater detail.
Furthermore, proline-rich cationic peptides containing several
hydrophobic residues, as is also the case with our design, were
shown to be efﬁcient CPPs [29], that may even be genetically encoded
[30]. Moreover, hydrophobic aromatic anions have been shown to act as
highly efﬁcient additives for the cell entry of oligoarginines [31,32]. We
envisioned that the presence of aromatic residues in the CPPs might
have a similar effect, perhaps aided by a charge screening through
cation-π interactions as observed for some AMPs [33]. Thus, in thework
presented here we investigated how the design of novel α-peptide/β-
peptoid chimeras may inﬂuence their uptake into mammalian cells as
well as the perturbation of mammalian cell and model membranes.
2. Materials and methods
2.1. Materials
Tat47–57 (YGRKKRRQRRR-NH2), magainin 2 (GIGKFLHSAKKFG-
KAFVGEIMNS) and N-terminally ﬂuorescein isothiocyanate (FITC)
labelled Tat47–57-peptide were purchased from GenScript Corporation
(NJ, USA). Amino acids, coupling reagents, and Rink amide resin for
solid-phase synthesis were from Novabiochem (Läufelingen, Switzer-
land). If not otherwise stated, compounds were supplied by Sigma-
Aldrich (Buchs, Germany).
2.2. Synthesis of peptidomimetics and peptides
Non-labelledα-peptide/β-peptoid chimeras (1, 3, 5, 7, and 9; Fig.1)
were prepared and characterised as previously reported [27,34].
2.2.1. Chemical synthesis of 5(6)-carboxyﬂuorescein-(CF) labelled
chimeras
Oligomerisation was performed by solid-phase peptide synthesis
as previously described [27,34], and the N-terminal was subsequently
acylated with CF (2 equiv), diisopropylcarbodiimide (DIC; 2 equiv),
and N-hydroxybenzotriazol (HOBt; 2 equiv) in dry N,N′-dimethylfor-
mamide (DMF: 4mL) for 16 h. The resinwas drained andwashed three
times with DMF, treated with 20% piperidine in DMF (4 mL,
2×10 min), and then washed three times with DMF, MeOH, and
CH2Cl2. The crude oligomers (2, 4, 6, and 8) were cleaved from the
solid support by treatment with triﬂuoroacetic acid (TFA)-CH2Cl2
(95:5, 4 mL, 1 h), and puriﬁed to homogeneity by preparative HPLC
[250×20 mm, Phenomenex C18(2) column, 5 μm]. A linear gradient of
eluent B (H2O-MeCN 5:95 with 0.1% TFA) in eluent A (H2O-MeCN 95:5
with 0.1% TFA) rising from 0% to 40% during 30 min, was applied. The
lyophilised products were analysed by RP-HPLC254 nm (N95% purity),
and stored at −20 °C.
2.2.2. Chemical synthesis of CF-labelled peptides
Solid-phase reactions were performed in Teﬂon ﬁlter vessels on a
Scansys PLS 4×6 Organic Synthesizer equipped with a heating block.
Fmoc-protected Rink amide resin (100 mg, 1 mmol/g) was treated
with 20% piperidine-DMF (4 mL, 2×10 min), and washed with DMF,
MeOH, and CH2Cl2 (3× each). The resin was agitated with a pre-
incubated (for 10 min) mixture of Fmoc-Lys(Boc)-OH (1.5 equiv for 10
and 11) or Fmoc-hArg(Boc2)-OH (1.5 equiv for 12), benzotriazol-1-yl-oxytripyrrolidinophosphonium hexaﬂuorophosphate (PyBOP: 1.5
equiv), and iPr2EtN (4 equiv) in dry DMF (1.5 mL) under N2 for 2 h,
andwas subsequently washedwithMeOH, DMF, and CH2Cl2 (3× each).
The resinwas treated with 20% piperidine-DMF (4mL, 2×10min), and
was washed with MeOH, DMF, and CH2Cl2 (3× each). This two-step
coupling/deprotection cycle was repeated 7 times for 11 and 12.
Finally, the N-terminal was acylated with CF (2 equiv), DIC (2 equiv),
and HOBt (2 equiv) in dry DMF (4 mL) for 16 h. Cleavage and
puriﬁcation were performed as above.
2.3. Cell culture
HeLa-cells were purchased from the American Type Culture
Collection (ATCC) and maintained in Eagle's Minimum Essential
Medium (EMEM) supplemented with 100 U/mL penicillin, 100 μg/
mL streptomycin, 2 mM L-glutamine, 0.1 mM non-essential amino
acids, 1 mM sodium pyruvate (all from Invitrogen A/S, Taastrup,
Denmark) (below referred to as complete EMEM), and 10% (v/v) fetal
bovine serum (FBS) (Fisher Scientiﬁc Biotech Line, Slangerup, Den-
mark). NIH3T3 cells were purchased from the ATCC andmaintained in
Dulbecco's Modiﬁed Eagle's Medium (DMEM) (Invitrogen A/S,
Taastrup, Denmark) supplemented with 100 U/mL penicillin, 100 μg/
mL streptomycin, and 2 mM L-glutamine (below referred to as
complete DMEM) and 10% (v/v) newborn calf serum (NCS) (Fisher
Scientiﬁc Biotech Line, Slangerup, Denmark). At 80% conﬂuency, cells
were subcultured approximately 1:5 (twice a week). Cells were grown
in an atmosphere of 5% CO2–95% O2 at 37 °C and growth media were
replaced every 48 h. Luciferase-expressing NIH3T3 cells were
prepared by co-transfection with pIS0 (expressing ﬁreﬂy luciferase)
and pIRES-Hyg (conferring resistance to hygromycin) plasmids into
NIH3T3 cells and subsequent selectionwith hygromycin B (300 μg/mL)
until a resistant cell population emerged.
2.4. Flow cytometry
Forty eight hours prior to peptide addition, HeLa-cells grown to
an 80% conﬂuent monolayer were detached from culture ﬂasks by
incubating the cells for 5 min at 37 °C with trypsin/EDTA solution.
The cells were seeded in 6-well (35 mm) tissue culture plates in 2 mL
complete EMEM containing 10% (v/v) FBS, 2×105 cells/well, and
incubated at 37 °C. After 48 h, the mediumwas removed and the cells
were washed with phosphate-buffered saline (PBS). The ﬂuorescently
labelled peptides/chimeras were dissolved in methanol and diluted
with PBS to a ﬁnal methanol concentration of 31% v/v. The cells were
incubated with fresh complete EMEM+10% (v/v) FBS (200 μL),
containing a total peptide/chimera concentration of 10 μM, for
60 min at 37 °C (n=3). The ﬁnal methanol concentration in the cell
culture medium was 1% v/v (for control cells, methanol was added to
the medium to a concentration of 1% v/v). The cells were then
washed three times with PBS, treated with 0.01% trypsin in PBS
(200 μL) at 37 °C for 10 min, washed twice with PBS containing 10%
(v/v) FBS by centrifugation and resuspended in ice-cold PBS
containing 10% (v/v) FBS (500 μL) and 10 μL propidium iodide (PI)
dissolved in PBS (50 μg/mL, Invitrogen, Taastrup, Denmark) for
staining of dead cells. The cells were analysed on a FACScan ﬂow
cytometer (Becton Dickinson, NJ, USA) using the CellQuest Software
(Becton Dickinson). Dead cells were excluded based on the PI-
staining. Washing the cells after trypsinisation in the presence of
4 mg/mL heparin (Sigma-Aldrich, Brøndby, Denmark) in PBS+10% (v/
v) FBS did not yield any signiﬁcant difference in the ﬂow cytometry
analyses (data not shown).
2.5. Confocal laser scanning microscopy
HeLa-cells (80% conﬂuent)were trypsinised and seeded onto 35mm
glass-bottomed Microwell dishes (MatTek Corporation, Ashland, MA,
Fig. 2. Flow cytometry analysis of HeLa-cells after 60 min incubation with 10 μM of the
CF-labelled α-peptide/β-peptoid chimeras 2, 6, and 8 at 37 °C. CF-labelled Lys (10),
hArg8 (12), and FITC-labelled Tat47–57 were used as controls. (A) Bars show cellular mean
ﬂuorescence intensity. Data represent mean±standard deviation of three samples. (B)
Representative histogram showing uptake of chimeras by HeLa-cells [10 (blue), 2
(green), and 6 (red)]. (For interpretation of the references to colour in this ﬁgure legend,
the reader is referred to the web version of this article.)
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were washed with PBS and incubated with fresh complete EMEMwith
10% (v/v) FBS (200 μL) containing thepeptides/chimeras (10 μM)at 37 °C
for 1 h. The cells were then washed ﬁve times with ice-cold PBS and
storedon ice in 0.5mLof PBS. Confocal imagingof unﬁxed cells (to avoid
artifactual localisation of internalised peptide or chimera) was
performed on a Zeiss LSM 510 confocal laser scanning microscope
(Carl Zeiss, Jena, GmBH, Germany), using a Zeiss plan apochromat 63×
oil immersionobjective. Fluorophoreswere excitedusing anargon laser
line at 458 nm and a HeNe laser line at 543 nm.
2.6. Luciferase permeability assay
Twenty four hours prior to analysis, NIH3T3 cells were seeded in
white 96-well tissue culture plates (Nunc) at a density of 30,000 cells/
well in 100 μL complete DMEMwith 10% (v/v) NCS. The cells were then
transferred to ice, the cell culture medium was removed, and the
chimeras (10 μM) were added in triplicate together with 50 μM
luciferin (Biosynth AG, Staad, Switzerland) in PBS in a total volume of
100 μL. Luminescence was measured immediately after peptide
addition using a FLUOstar OPTIMA plate reader (BMG Labtech
GmbH, Offenburg, Germany) with luminescence optics preset at 37 °C.
2.7. Preparation of liposomes
Unilamellar empty liposomes (7 mM) or liposomes (2 mM) encapsu-
lating self-quenching concentrations of calcein were prepared from
palmitoyl-oleoyl PC (POPC) and POPC-palmitoyl-oleoyl phosphatidylgly-
cerol (POPG) in a 8:2 molar ratio, or from dipalmitoyl PC (DPPC) and
DPPC-DPPG (8:2molar ratio) as previously described [35]. For determina-
tion of lipid concentration trace amounts of dipalmitoylphosphatidyl[N-
methyl-3H]choline (3H-DPPC, speciﬁc activity 3.11 TBq/mmol) (GEHealth
Care, Hillerød, Denmark) were added prior to solvent evaporation on a
rotary evaporator. The lipid ﬁlms were then stripped three times with
ethanol and dried overnight under reduced pressure to remove trace
amount of organic solvent. Multilamellar vesicles were prepared by
dispersing the dried lipid ﬁlms in 6 mL HEPES-buffer I (10 mM HEPES,
50 mM KCl, 1 mM NaN3, pH 7.5) to give empty liposomes, or in 4 mL
HEPES-buffer II (10 mM HEPES, 150 mM KCl, 1 mM NaN3, 30 μM CaCl2,
10 μM NaEDTA, pH 7.5) containing 20 mM calcein to give calcein-
containing liposomes. The formed liposomes were subsequently
extruded 10 times through two stacked 100-nm polycarbonate ﬁlters
using anextruder fromLipexBiomembranes Inc. (Vancouver, BC, Canada).
The particle size distributionwas determined by dynamic light scattering
using the photon correlation spectroscopy (PCS) technique. Themeasure-
mentswere performed on samples dilutedﬁve times inHEPES-buffer I or
II (n=3) at 25 °C using a Malvern NanoZS (Malvern Instruments,
Worcestershire, UK) equipped with a 633 nm laser and 173° detection
optics. Malvern DTS v. 4.20 software (Malvern Instruments, Worcester-
shire, UK) was used for data acquisition and analysis. A polystyrene size
standard (220±6 nm, Duke Scientiﬁc Corp., Palo Alto, CA, USA) was used
to verify the performance of the instrument. All liposome preparations
had a narrow size distribution (polydispersity indexes of approximately
0.1) with a mean diameter of approximately 100 nm (data not shown).
Non-encapsulated calcein was removed by gel ﬁltration (Sephadex G-50
column, GE Healthcare, Hillerød, Denmark) using HEPES II buffer as the
eluent. The phospholipid content was either determined by liquid
scintillation counting with a Packard TRI-CARB 2100 TR scintillation
counter from Packard Instruments using Ultima Gold scintillation ﬂuid
(Perkin Elmer, Boston, USA) or by the Phospholipid B enzymatic kit (Team
ProDiagnostica GmbH —MTI-Diagnostics, Germany).
2.8. Calcein release assay
The calcein release assay was performed essentially as described
previously [36]. The chimeras were serially diluted in triplicate in a96-well plate, and the liposome suspension was added to provide a
ﬁnal lipid concentration of 25 μM (180 μL total volume). At this lipid
concentration, the calcein concentration after 100% release was
shown to be in the linear range of the calcein standard curve (0–
1.5 μM) under the applied experimental conditions. The samples
were incubated for 1 h at 37 °C, and the calcein ﬂuorescence in the
medium was measured using a FLUOstar OPTIMA plate reader at an
excitation wavelength of 485 nm and an emission wavelength of
520 nm. Calcein leakage was expressed relative to the difference in
the ﬂuorescence between calcein liposomes incubated in the
absence of chimeras (0% leakage) and the ﬂuorescence of calcein
liposomes that had been disrupted with 20 μL (1% v/v) Triton X-100
(100% leakage). The effect of Triton X-100 on calcein ﬂuorescence
intensity was negligible at the tested concentration (results not
shown).
2.9. Differential scanning calorimetry (DSC)
The gel-to-liquid phase transition temperature of DPPC liposomes
in the presence of the chimeras at lipid to peptide molar ratios of
500:1, 100:1, 25:1, and 10:1 (mixed immediately before analysis) was
determined using DSC. The total lipid concentration in all of the DSC
experiments was 1 mM. Thermograms were obtained using a
MicroCal VP-DSC MicroCalorimeter (MicroCal LLC, Northamton,
USA), scanning at a rate of 30 °C/h from 22 °C to 55 °C [8]. VPViewer
2000 and Origin® 7 scientiﬁc plotting software (OriginLab,
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scans of each sample (n=3) was used for data analysis.
2.10. Statistics
Experiments were performed in triplicate, if not otherwise stated.
Values are given as means±SD. The statistical signiﬁcance of the
results was determined using a Student's t-test where Pb0.05 was
considered signiﬁcant.Fig. 3. Confocal microscopy analysis of living HeLa-cells incubated with chimeras (10 μM) at 3
The scale bar represents 20 μm.3. Results
3.1. Synthesis of cell-penetrating oligomers
The structures of the investigated chimeras and peptides are
shown in Fig. 1. The chimeras are composed of cationic α-amino acid
residues [Lys or guanidinylated Lys=homoarginine (hArg)] and
lipophilic β-peptoid residues. Chiral or achiral β-peptoid residues
were incorporated, and constructs (1, 3, 5, and 7) with different7 °C for 60 min. (A): 10, (B): FITC-Tat47–57, (C): 2, (D): 4, (E): 6, (F): 8, (G): 11, and (H): 12.
Fig. 4.α-Peptide/β-peptoid chimera-inducedmembrane permeabilisation of luciferase-
expressing NIH3T3 cells. NIH3T3 cells transfected with luciferase (3×104 cells/well in
96-well plates) were treated with chimeras (10 μM) and luciferin (50 μM). The graphs
show light emission as a function of incubation time (mean of three samples, error bars
omitted for clarity).
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chimeras (2, 4, 6, and 8), as well as control peptides CF-Lys (10), CF-
Lys8 (11) and CF-hArg8 (12), were prepared.
3.2. Flow cytometry: guanidinylated chimeras are taken up 4-fold more
efﬁciently than Tat47–57 and hArg8
In previous studies it was shown that lysine-containing analogue 2
rapidly entered HeLa-cells when applied at a concentration of 10 μMFig. 5. α-Peptide/β-peptoid chimera-induced leakage of calcein across unilamellar liposomes
relative to the difference between leakage of calcein from liposomes after disruptionwith Tri
(0% value). Each data point represents the average of three individual measurements±stand[28]. To validate this analysis further and to quantify the cellular
uptake of various chimeras, HeLa-cells were treated with N-terminally
CF-labelled chimeras/peptides at 37 °C for 60 min. The ﬂuorescence
indicative of the amount of the respective peptides taken up by the
cells was quantiﬁed by ﬂow cytometry (Fig. 2). Additional washing
with heparin did not inﬂuence the ﬂow cytometry results, showing
that the bulk of the peptides adsorbed at the cell surface was removed
during the trypsin treatment. Thus, our data reﬂect the total cellular
uptake of the peptides, which also parallels experiments with Arg8
reported by Nakase et al. [37]. The lysine-containing chimera 2
displayed similar levels of uptake as found for the Tat47–57-peptide,
while functionalising the side chain amino groups with guanidino
groups increased the uptake about 10-fold, as seen for chimeras 6 and
8. The uptake levels of 6 and 8 were not signiﬁcantly different, which
implies that the presence of chirality in the β-peptoid side chains does
not enhance the cellular uptake. Guanidinylated peptide 12 showed
uptake in the same range as Tat47–57. No apparent cytotoxicity of the
chimeras (lack of PI uptake) was observed at the applied chimera
concentrations in this assay.
3.3. Chimeras localise in vesicular compartments and in the cytoplasm
Using confocal laser scanning microscopy, the peptide internalisa-
tion was studied in live HeLa-cells, since ﬁxation has been shown to
cause artifactual cellular localisation of peptides [38,39]. For all
chimeras, cellular ﬂuorescence was localised in vesicular structures
and little or no ﬂuorescence was present at the membrane surface or
in the nucleus (Fig. 3). However, some diffusive ﬂuorescence was
apparently localised in the cytoplasm. Fluorescently labelled Tat47–57
and the control hArg8 (12) were taken up more efﬁciently than Lys8
(11), but the intracellular localisation pattern of these peptides
appeared similar, with vesicular as well as diffusive cytoplasmic and
some nuclear staining.(25 μM) at 37 °C as a function of chimera concentration. Leakage of calcein is expressed
ton X-100 (100% value) and leakage of calcein from liposomes in the absence of peptides
ard deviation.
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cells
To determine whether the chimeras possess a permeability-
enhancing effect on cell membranes, a permeability assay with
luciferase-expressing NIH3T3 murine ﬁbroblasts was applied.
Together with the luciferase substrate, luciferin, the chimeras were
added to the cells at 4 °C, and the light emission was measured
immediately upon transferring the cells from ice to a plate reader
preset at 37 °C. The guanidinylated chimera 5was more efﬁcient than
the corresponding amine-functionalised chimera 1, resulting in a
higher initial light emission due to a higher immediate cellular inﬂux
of luciferin (Fig. 4). This immediate effect was also observed for the
control AMP magainin 2. Increasing the chain length repeat from 6 to
8 increased the initial light emission for both 1 vs 3 and 5 vs 7,
respectively. In all cases except for 7, the light emission reached a
steady state after approximately 400 s, presumably corresponding
to equal consumption and production of ATP by the cells. For the
Tat47–57-peptide, no initial change in cellular permeability was observed
as compared to the control cells that were incubated with buffer alone.
However, between 100–150 s, the Tat47–57-peptide was able to increase
the luciferin inﬂux to an extent, whichwas signiﬁcantly higher than the
buffer control (P=0.006).
3.5. α-Peptide/β-peptoid chimeras induce calcein release from POPC,
POPC–POPG, DPPC and DPPC–DPPG vesicles
To examine how the chimeras affect the stability and permeability
of model membranes, we tested the capacity of three α-peptide/β-
peptoid chimeras (3, 7, and 9) to induce leakage of calcein from
unilamellar liposomes in ﬂuid phase (POPC) and in gel phase (DPPC).
In addition the effect of inclusion of 20% (molar ratio) of negatively
charged lipid (POPG or DPPG) was investigated. Fig. 5 shows the
results observed after 60 min of incubation at 37 °C in the presence of
increasing chimera concentrations. Calcein leakage occurred for both
3 and 7 with the guanidinium-containing chimera (7) being the most
potent. The constructs were more efﬁcient in inducing release of
calcein from gel state vesicles (DPPC) than from ﬂuid state vesicles
(POPC), and the inclusion of negatively charged lipids (DPPG or POPG)
affected the release. The non-cationic control, chimera 9, did not
induce any calcein release in the tested concentration range, showing
that the positive charges are essential for membrane destabilisation as
expected.Fig. 6. Phase transition enthalpy (ΔH) of unilamellar DPPC liposomes (1 mM) in the
presence of various amounts of peptides (corresponding to lipid/peptide molar ratios of
10:1, 25:1, 100:1 and 500:1). Mean±standard deviation of three samples are given. Data
for the ﬁrst scan is shown.3.6. Effect on the thermothropic phase behavior of DPPC membranes
The thermothropic phase behaviour of DPPC model membranes
was characterised by DSC to examine the membrane-destabilising
effect of the α-peptide/β-peptoid chimeras biophysically. Chimeras (1
or 5) were mixed in different ratios with DPPC liposomes and analysed
by DSC. There was no signiﬁcant change in the main phase transition
temperature, suggesting that the binding of chimeras to the
membrane does not affect the packing of the membrane bilayer
(results not shown). The enthalpy of the main transition, however,
decreased in a concentration-dependent manner in the presence of 1
and 5 (Fig. 6). The effect was statistically signiﬁcant even at a lipid/
peptide molar ratio of 100:1 and reached a plateau at approximately
40 μM (lipid/peptide molar ratio of 25:1), with the hArg-based 5 being
signiﬁcantly more potent than the Lys-based 1 at concentrations of
10 μM and above.
4. Discussion
The experiments with HeLa-cells show that the ﬂuorescently
labelled chimeras possess efﬁcient cellular uptake properties that are
superior to those of the well-described CPPs (i.e., various polycationic
α-peptides such as Tat-peptide fragments). In particular, the guani-
dino-functionalised peptidomimetics were efﬁciently translocated
into HeLa-cells, which parallels previous observations reported for β-
peptides [40,41] and other backbone constructs [42–45]. Furthermore,
a comparison of the uptake of 11 vs 12 as well as that of 2 vs 6 shows
that guanidinylation increases uptake signiﬁcantly, as also reported
for β-peptides [40]. Not surprisingly, the data for the control peptide
12 were very similar to those for the arginine-rich Tat47–57-peptide.
More interestingly, the uptake of 2was also in the same range as found
for the former peptides, which shows that the cellular uptake of
amino-containing compounds may be enhanced by increasing the
overall lipophilicity. This trend is also evident when comparing the
uptake of chimeras 6 and 8 to the highly hydrophilic peptides 12 and
Tat47–57.
While chirality of the β-peptoid residues may inﬂuence the
antimicrobial potency of α-peptide/β-peptoid chimeras [27], it does
not appear to be of importance for their cellular uptake, since
chimeras 6 and 8 are equipotent. This ﬁnding is in accordancewith the
general perception that secondary structure is important for the
activity of cationic AMPs, whereas efﬁcient CPPs like oligoarginines
and Tat-peptides are likely to be unstructured. In fact, stable helical
conformations and reduced ﬂexibility have also previously been
reported to impede cellular uptake of CPPs [46], although a recent
study suggests that a stable helix conformation of CPPs can increase
uptake in certain cases [47].
The intracellular localisation studies showed that chimeras were
distributed into vesicular compartments, and diffusive staining in
the cytoplasm of HeLa-cells was observed, which suggests that an
endocytotic process may be involved in the uptake at the applied
peptide concentration (10 μM). Yet, a physically driven transduc-
tion mechanism where the membrane is directly transversed [48–
50] cannot be abandoned based on our current results, and further
studies addressing this issue are underway. The localisation results
support the ﬁnding from the ﬂow cytometry studies, where 11, 12,
and Tat47–57 are likewise taken up in a different fashion compared
to the chimeras 6 and 8. The latter show only slightly diffusive
staining of the cytoplasm and no nuclear staining, whereas the
former non-hydrophobic peptides show some staining of both the
cytoplasm and the nuclei. The chirality of the β-peptoid units
affected neither the uptake levels nor the localisation of the
intracellular chimeras. It cannot be ruled out, however, that the
CF-labelling might change the activity of the chimeras and thus
the intracellular localisation pattern compared to unlabelled
chimeras.
2494 C. Foged et al. / Biochimica et Biophysica Acta 1778 (2008) 2487–2495The cell membrane permeabilising properties of the chimeraswere
measured by co-addition of chimeras and the substrate luciferin to
luciferase-expressing NIH3T3 cells using light emission as read-out for
permeability changes. The chimeras induced immediate membrane
permeabilising effects, with the longer oligomers (8 repeats) being
more efﬁcient than the shorter oligomers (6 repeats). The guanidi-
nium-functionalised chimeras were again more potent than their
amine-functionalised counterparts. Compound 3 exhibited potent
permeability with a more or less constant light emission, while
compound 7 gave rise to a slight decrease in light emission over time,
which may suggest a compromise of the cell membrane integrity. The
effects of the type of cationic group along with the effects of chain
length are in agreement with our previous ﬁndings that increased
chain length results in a higher hemolytic activity for guanidinylated
chimeras, whereas no hemolysis and very little prehemolytic mem-
brane changes were observed with lysine-containing chimeras [28].
Interestingly, the homoarginine-containing dodecamer 5 gave rise to a
lower degree of perturbation of the NIH3T3 cells than the lysine-
containing hexadecamer 3. This shows that cell permeability is highly
dependent on chain length, and suggests that oligomers containing
both hydrophobic and guanidinylated side chains may be acceptable
with respect to toxicity as long as the chain length is kept low. The
natural AMP, magainin 2, behaved similarly with an intermediate
activity as compared to the dodecamers 1 and 5, while the Tat47–57-
peptide showed no signiﬁcant initial change in cellular permeability
compared to the control cells (incubated with buffer). After 100–150 s,
the Tat47–57-peptidewas able to cause an increase in the luciferin inﬂux
as compared to the buffer-treated cells.
To examine the membrane effects of these chimeras further,
biophysical experiments using liposomal model membranes (dye
release and DSC) were performed. The two chimeras 3 and 7 induced
calcein release of ﬂuid phase POPC and gel phase DPPC unilamellar
vesicles. The homoarginine-containing chimera 7 was more potent
than the lysine-containing chimera 3 for both vesicle types. This is in
agreement with our cellular experiments as well as previous
observations that arginine-rich peptides generally bind membrane
lipids stronger than their lysine counterparts due to their ability to
form bidentate hydrogen bonds to the negatively charged oxygen
atoms of the zwitterionic phospholipid head groups, as compared to
monodentate hydrogen bonding capability of protonated amines
[20,43,51]. For guanidinium-rich peptides it has been suggested that
such binding leads to formation of transient membrane-soluble ion-
pair complexes, and that the latter partition into the lipid bilayer and
mediate adaptive diffusion of the peptides into the hydrophobic
membrane [20,52]. This effect might account for the fact that our
chimeric constructs containing hydrophobic β-peptoid residues
destabilise membranes more readily as a result of enhanced diffusion
into the lipid membrane. This hypothesis is in agreement with the
superior performance of the chimeras in the cellular experiments and
data reported in the literature for other amphipathic peptide
constructs [29,53,54].
The ﬂuidity of the membrane bilayer clearly inﬂuenced the calcein
release. Lower degrees of release were observed for ﬂuid phase POPC
liposomes than for gel phase DPPC liposomes. This corresponds well
with the increased lateral diffusion of unsaturated phospholipids,
which upon peptide binding to a large extent are able to preserve the
barrier properties of the membranes (annealing effect), compared to
saturated lipids with lower lateral diffusion constants.
Intuitively, introduction of negatively charged lipid head groups at
the membrane surface by replacing part of the PC with the negatively
charged phospholipid PG would be expected to increase binding of
chimeras to the membrane, resulting in release of calcein at lower
concentrations. This was not the case for ﬂuid phase POPC liposomes,
where introduction of 20% mol/mol POPG did not change the release
signiﬁcantly. However, upon introducing 20% mol/mol DPPG into the
membranes of gel state DPPC liposomes, calcein leakage was indeedincreased, suggesting that the interactionmodes with the zwitterionic
and negatively charged membranes differ to some extent but in a
manner largely dependent on the ﬂuidity of the lipid bilayer (ﬂuid or
gel phase).
DSC has proven to be a valuable tool in examining interactions
between AMPs and lipids [55]. The main phase transition represents
the conversion from a gel phase to a liquid crystalline phase. This
transition is strongly inﬂuenced by the mode of packing of the acyl
chains of the phospholipid molecules. The chimeras did not affect the
main phase transition temperature of DPPC liposomes signiﬁcantly
(results not shown), which suggests that they do not disrupt the
packing of the phospholipid membrane. The enthalpy of the main
phase was reduced in a concentration-dependent manner in the
presence of 5 (and to a lesser extent of 1), whichmay be explained by a
decrease in entropy change (ΔS=ΔH/Tm), suggesting that the lipid
molecules in the membrane become more ordered in the presence of
the chimeras. This indicates that the overall lateral movements in the
lipid bilayer are restricted in a way that changes the permeability of
the bilayer. Above the phase transition temperature this leads to
diminished positional disorder and reduced lateral diffusion, resulting
in a lesser degree of motional freedom and thereby a lower entropy.
These data suggest that the effect of the chimeras do not result in a
toroidal pore formation as described for magainin 2, where peptide
molecules do translocate stochastically into the cytosol [25,56]. It
rather points to the possibility that the chimeras are adsorbed on the
surfacewith the hydrophilic parts of themolecule protruding from the
membrane surface and the hydrophobic parts immersed into the
membrane hydrocarbon phase (i.e., a “carpet-like mechanism” [57] or
adaptive translocation [52]).
5. Conclusion
In summary, our investigations have shown that antimicrobial/
antiplasmodial α-peptide/β-peptoid chimeras serve as structural
starting points for the construction of efﬁcient CPPs, which interact
with several types of biological and model membranes by a mechan-
ism differing from that of polycationic CPPs inspired by Tat protein.
Contrary to the commonperception that AMPs require a high degree of
secondary structure, this does not appear to be a requirement when
designing CPPs. We have also shown that introduction of lipophilic
groups enhances the cellular uptake, and may even make up for the
loss of activity brought about by substituting guanidino functionalities
with amino groups. These ﬁndings support the prospect ofmodulating
the structure of the chimeric peptidomimetics with respect to overall
lipophilicity, as well as type and number of cationic groups, in the
search for efﬁciency and membrane selectivity. Thus, the mechanistic
differences observed between the various probes in this investigation
have revealed valuable knowledge for the future design of CPPs. We
envisionα-peptide/β-peptoid chimeras as useful, enzymatically stable
tools for the study of both cell-penetrating and antimicrobial proper-
ties. However, the trends observed in the present paper should not be
restricted to biomimetic oligomers with this particular backbone [58].
We are currently designing new generations of chimeras in the search
for improved membrane selectivity as well as cell-penetrating ability
for various types of cargo.
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